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Summary
 
Cholera toxin (CT), the most commonly used mucosal adjuvant in experimental animals, is
unsuitable for humans because of potent diarrhea-inducing properties. We have constructed
two CT-A subunit mutants, e.g., serine
 
®
 
phenylalanine at position 61 (S61F), and glutamic
acid
 
®
 
lysine at 112 (E112K) by site-directed mutagenesis. Neither mutant CT (mCT), in con-
trast to native CT (nCT), induced adenosine diphosphate-ribosylation, cyclic adenosine mono-
phosphate formation, or fluid accumulation in ligated mouse ileal loops. Both mCTs retained
adjuvant properties, since mice given ovalbumin (OVA) subcutaneously with mCTs or nCT,
but not OVA alone developed high-titered serum anti-OVA immunoglobulin G (IgG) anti-
bodies (Abs) which were largely of IgG1 and IgG2b subclasses. Although nCT induced brisk
IgE Ab responses, both mCTs elicited lower anti-OVA IgE Abs. OVA-specific CD4
 
1
 
 T cells
were induced by nCT and by mCTs, and quantitative analysis of secreted cytokines and
mRNA revealed a T helper cell 2 (Th2)-type response. These results now show that the toxic
properties of CT can be separated from adjuvanticity, and the mCTs induce Ab responses via a
Th2 cell pathway.
 
T
 
he major enterotoxins produced by 
 
Vibrio cholerae
 
 and
 
Escherichia coli
 
, termed cholera toxin (CT)
 
1
 
 and heat-
labile toxin (LT), respectively, are multisubunit macromol-
ecules composed of two structurally, functionally, and immu-
nologically separate A and B subunits (1–3). The B subunit
of each toxin consists of five identical 11.6-kD peptides,
but differ from each other in that the B subunit of CT
(CT-B) only binds to GM1 ganglioside (4), whereas the B
subunit of LT (LT-B) binds GM1 as well as asialo GM1
and GM2 (5). After the B subunit binds to epithelial cell
GM1 or GM2 receptors, the A subunit reaches the cytosol,
and after activation, binds to nicotinamide adenosine diphos-
phate  and catalyzes ADP ribosylation of Gs-
 
a
 
 (6). This
GTP-binding protein activates adenyl cyclase with subse-
quent elevation of cAMP, which in epithelial cells results in
secretion of water and chloride ions into the small intestine (7).
Both CT and LT are immunogenic and mucosal expo-
sure results in secretory IgA (S-IgA) and serum Abs, which
are almost entirely restricted to CT-B or LT-B (8, 9). Fur-
ther, both toxins are also strong mucosal adjuvants for
coadministered, unrelated protein Ags when given by oral,
intranasal, or parenteral routes (8–10). We have shown that
induction of maximal mucosal S-IgA and serum IgG Ab
responses correlated directly with Ag-specific CD4
 
1
 
 Th
cells secreting IL-4 and IL-5 in mice orally immunized
with protein Ag and CT as adjuvant (10). Further, detailed
analysis showed that CT elicits adjuvant responses by in-
ducing Ag-specific CD4
 
1
 
 Th2-type cells which produce
high levels of IL-4 and IL-5, responsible for supporting
subsequent development of systemic IgG1 and IgG2b sub-
class, IgE and S-IgA Ab responses (11). On the other hand,
oral immunization with LT promotes IgM, IgG1, IgG2a,
IgG2b, and S-IgA Ab responses, which are supported by a
mixed CD4
 
1
 
 Th1- and Th2-type response associated with
 
1
 
Abbreviations used in this paper:
 
 AFC, antibody-forming cell; CHO, Chi-
nese hamster ovary; CT, cholera toxin; ELISPOT, enzyme-linked immu-
nospot; LT, heat-labile toxin; m, mutant; n, native; r, recombinant; RT,
reverse transcriptase; S, secretory.
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Nontoxic Mutants of Cholera Toxin Induce Th2-type Responses
 
IFN-
 
g
 
, IL-4, IL-5, IL-6, and IL-10 production (12). Fur-
thermore, when IL-4 levels produced by CD4
 
1
 
 T cells were
compared when CT or LT were used as adjuvants, Ag-spe-
cific IL-4 production was lower when LT was used (11, 12).
Earlier studies have attempted to dissociate toxicity from
adjuvanticity of CT and LT; however, it was shown that a
mutant LT toxin, E112K, which had single amino acid
substitution in the ADP-ribosyltransferase active center,
was nontoxic and also lacked adjuvanticity (13). Recently,
two groups have reported that single amino acid substitu-
tion mutants of LT, R7K, and R192G, which are outside
of the ADP-ribosyltransferase cleft, were nontoxic, but re-
tained adjuvant properties (14, 15). However, one of these
LT mutants retained some ADP-ribosyltransferase activity
and could potentially cause diarrhea in humans.
To develop an ideal nontoxic mucosal adjuvant, we con-
structed two CT mutants, S61F and E112K, by site-directed
mutagenesis, which have single amino acid substitutions in
the ADP-ribosyltransferase active center (16). Neither mu-
tant showed toxic activity, and in the present study these
mutants were used to assess adjuvant properties as well as
signaling pathways involved in adjuvanticity.
 
Materials and Methods
 
Construction and Purification of CT Mutants.
 
A 3.1-kb EcoRI/
PstI DNA fragment including the CT gene (17) from 
 
V. cholerae
 
O1 strain GP14 was cloned into phage M13mp19. Single strand
DNA was prepared from a culture supernatant of 
 
E. coli
 
 CJ236
transfected with M13mp19 including the CT gene and was sub-
jected to a site-directed mutagenesis system using Mutan K
(Takara Biomedicals, Kyoto, Japan) as described previously (18).
The sequences of oligonucleotides used for the serine to phenyl-
alanine substitution at position 61 (S61F) and for the glutamate to
lysine mutation at position 112 (E112K) were 5
 
9
 
-GGATAT-
GTTTTTACCTCAATT-3
 
9
 
 and 5
 
9
 
-GATGAACAAAAAGTT-
TCTGCT-3
 
9
 
, respectively. The amino acid mutation sites (i.e.,
61 and 112) are both in the CT-A subunit, located in the proposed
ADP-ribosyltransferase active center of CT (16), and substitution
of these amino acids in LT have been shown to completely inac-
tivate ADP-ribosyltransferase activity and enterotoxicity (19, 20).
After the DNA sequences were confirmed, pUC119 harboring
the mutated CT genes at the EcoRI/PstI site were transformed
into 
 
E. coli
 
 DH5-
 
a
 
.
 
 
 
E. coli
 
 strains containing the plasmids for the
mutant CT genes were grown in LB medium (10 g NaCl, 10 g
tryptone, and 5 g yeast extract/liter) with 100 
 
m
 
g/ml of ampicil-
lin, and CT mutants were purified using a D-galactose immobi-
lized column (Pierce Chem. Co., Rockford, IL) from a cell sus-
pension prepared by sonication. A plasmid containing the recombinant
CT-B (rCT-B) gene (21) was provided by Dr. Charles O. Elson
(University of Alabama at Birmingham, Birmingham, AL) and CT-B
was also purified by use of a D-galactose immobilized column.
 
Biologic, Enzymatic, and Toxicity Assays of Mutant CTs.
 
The abil-
ity of CT mutants (mCTs) and native CT (nCT) to induce toxic
effects in cultured Chinese hamster ovary (CHO) cells was done
as previously described (22). In brief, log
 
10
 
 dilutions of each toxin
were added to CHO cell cultures (2 
 
3
 
 10
 
5
 
 cells/0.5 ml of F10
medium containing 1% FCS) and cultured at 37
 
8
 
C in 5% CO
 
2
 
 for
24 h. Toxicicty was defined as spindle formation in 
 
.
 
20% of cell
cultures. For cAMP assessment, 10
 
6
 
 CHO cells in F10 medium
containing 1% FCS were cultured with 1 ng/ml of mCTs or
nCT for 24 h as described above. The cellular protein precipi-
tated with 5% trichloroacetic acid was dissolved in 0.2 N NaOH
and the protein amount was determined (BioRad Labs., Her-
cules, CA). The supernatants were assessed for cAMP with an en-
zyme immunoassay system (Amersham Intl., Buckinghamshire,
UK), and the levels of cAMP were expressed as pmol of cAMP/mg
of protein.
 
ADP-ribosyltransferase Activity of mCTs.
 
The CT-A–catalyzed
transfer of ADP-ribose from nicotinamide adenosine diphosphate
to agmatine was done precisely as described previously (23). In
brief, each assay tube contained 10 
 
m
 
g of mCTs or nCT in a total
volume of 300 
 
m
 
l and a 50 
 
m
 
l aliquot of the assay mixture was as-
sessed for radioactive ADP-ribosylated agmatine by liquid scintil-
lation counting.
 
Assessment of Toxicity Using Mouse Ileal Loops.
 
The enterotox-
icity of mCTs and nCT was examined using a mouse ileal loop
test (24). Groups of mice were anesthetized, and 100 
 
m
 
l of PBS
containing different doses of each toxin were injected into a 2-cm
ileal loop, which was isolated by suture. The mice were killed 18 h
after the injection, and the ratio of fluid to length was determined
and defined as positive when the ratio was more than 40 
 
m
 
l/cm.
 
Mice and Their Immunization.
 
C57BL/6 mice were obtained
from the Frederick Cancer Research Facility (National Cancer In-
stitute, Frederick, MD) at 5–6 wk of age, and were used at 8–12 wk
of age. Mice were immunized subcutaneously with 100 
 
m
 
g of
OVA (Sigma Chemical Co., St. Louis, MO) alone or together
with 10 
 
m
 
g of mCTs (S61F or E112K), with 1 
 
m
 
g of nCT (List
Biological Labs., Campbell, CA), or with 10 
 
m
 
g of rCT-B on
days 0 and 14.
 
Detection of Ag-specific Abs by ELISA and Antibody-forming Cells
by Enzyme-linked Immunospot (ELISPOT) Assay.
 
Ab titers in serum
were determined by ELISA and splenic antibody-forming cells
(AFCs) by enzyme-linked immunospot (ELISPOT) assay as de-
scribed previously (10, 11). Endpoint titers determined by ELISA
were expressed as the reciprocal log
 
2
 
 of the last dilution giving an
OD
 
450
 
 of 
 
>
 
0.1 above unimmunized controls. In the ELISPOT
assay, the AFCs were determined by direct counting of spots as
described before (10, 11).
 
IgE Analysis.
 
Total IgE levels were determined by ELISA as
described previously (11). Ag-specific IgE was detected by a modi-
fied IgE capture method (25). In brief, 96-well microplates (Dy-
natech Labs, Inc., Chantilly, VA) were coated with 1 
 
m
 
g/ml of rat
anti–mouse IgE mAb (PharMingen, San Diego, CA) in 50 mM
carbonate-bicarbonate buffer (pH 9.5). After blocking with 3%
BSA-PBS, serial dilutions of serum were added. After incubation
and washing, 2.5 
 
m
 
g/ml of biotinylated OVA or 1.5 
 
m
 
g/ml of
CT-B (prepared as described previously [25]) were added in 3%
BSA-PBS-Tween 20. The plates were then washed with 2 mM
EGTA-PBS-Tween 20 and incubated with 10 ng/ml strepta-
equorin (SeaLite Sciences, Norcross, GA) in 2 mM EGTA-PBS-
Tween 20. Light development was carried out in a luminometer
(ML-3000; Dynatech Labs., Inc.) by injection of Ca
 
2
 
1
 
 buffer (50
mM Tris, 20 mM calcium acetate, pH 7.5) (26). Endpoint titers
were determined as the dilution of each sample showing a two-
fold higher level of luminometric units above background.
 
OVA- and CT-B–specific Splenic CD4
 
1
 
 T Cell Responses.
 
Sin-
gle spleen cell suspensions in complete RPMI 1640 medium were
fractionated on a nylon wool column for 1 h at 37
 
8
 
C to remove
adherent cells. The CD4
 
1
 
 T cell subset (
 
.
 
98% purity) was then
obtained by positive sorting using a magnetic bead–activated cell
separation system (Miltenyi Biotec Inc., Sunnyvale, CA) using bi-
otinylated anti-CD4 mAb (GK1.5) and streptavidin-coated mi- 
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crobeads (Miltenyi Biotec Inc.). Purified splenic CD4
 
1
 
 T cells were
cultured at a density of 2 
 
3
 
 10
 
6
 
 cells/ml with 1 mg/ml of OVA
or with 10
 
7
 
 CT-B–coated beads/ml, T cell–depleted, irradiated
(3,000 rads) splenic feeder cells (2.5 
 
3
 
 10
 
6
 
 cells/ml), and IL-2 (10
U/ml; PharMingen) in complete medium (10, 11). As positive
controls, CD4
 
1
 
 T cells from nonimmunized mice were stimu-
lated with a solid-phase anti–mouse CD3 mAb (145-2C11). To
measure cell proliferation, 0.5 
 
m
 
Ci of [methyl-
 
3
 
H]thymidine (Du
Pont New England Nuclear Products, Boston, MA) was added to
individual culture wells 18 h before termination, the cells were
harvested, and the radioactivity was assessed by liquid scintillation
counting after 96 h of culture. To determine cytokine production
by Ag-specific CD4
 
1
 
 T cells, the cells were harvested after 48 h
of culture for quantitative reverse transcriptase (RT)–PCR analy-
sis of cytokine-specific mRNA and the supernatants were col-
lected after 96 h for evaluation of cytokines by ELISA. For IL-2,
supernatants from 48-h cultures were used, since this represented
the interval for maximal production of this cytokine.
 
Cytokine Analysis by ELISA.
 
Cytokines in culture supernatants
were determined by a modified ELISA (11). Nunc-Immu-
noMaxiSorp
 
TM
 
 plates were coated with 2.5 
 
m
 
g/ml of anti–mouse
IFN-
 
g
 
, IL-2, IL-4, IL-5, IL-6, or IL-10 mAb (PharMingen). For
secondary Abs and detection enzyme, 0.2 
 
m
 
g/ml of biotinylated
rat anti–mouse cytokine mAb (PharMingen) and 1:4,000 diluted
horseradish peroxidase–labeled antibiotin (Vector Labs., Inc.,
Burlingame, CA) were used, respectively.
 
Quantitative RT-PCR Analysis of Cytokine-specific mRNA.
 
Quantitative cytokine-specific RT-PCR using rRNA internal stan-
dards was conducted as described previously (11, 27, 28). Cytokine-
specific rRNA for IFN-
 
g
 
, IL-2, IL-4, IL-5, IL-6, or IL-10 were
used as internal standards (28). For quantitation, aliquots of total
RNA were added with a series of diluted rRNA internal stan-
dards (11, 28) and standard RT-PCR was performed as described
elsewhere (27). Analysis of PCR products was conducted by cap-
illary electrophoresis with a laser-induced fluorescence detection
system (LIF-P/ACE; Beckman Instrs. Inc., Fullerton, CA) (27).
 
Statistical Analysis.
 
The results are expressed as the mean 
 
6
 
SEM. Statistical significance (
 
P
 
 
 
,
 
0.05) was determined by Student’s 
 
t
 
test and by the Mann-Whitney U test of unpaired samples.
 
Results
 
Enzymatic Properties and Toxicity of mCTs.
 
A tandem of
biologic functions of mCTs was done to compare their en-
zymatic properties with nCT. As expected, as little as 1.0
pg/ml of nCT induced spindle cell formation in CHO cell
cultures, a response previously shown to be dependent upon
adenyl cyclase–mediated increases in cAMP (22). How-
ever, neither mCT affected the appearance of CHO cells,
even at levels of 1.0 
 
m
 
g/ml. These results were confirmed
by direct measurement of intracellular cAMP levels in CHO
cells, which were sharply increased in nCT-treated, but not
in mCT-treated cultures (Table 1). Quantitative analysis of
ADP-ribosyltransferase activity was assessed, and increased
enzymatic activity was again associated with nCT but not
with mCTs (Table 1). The toxicity of mCTs and nCT was
also assessed in a mouse ileal loop assay, where as little as
100 ng of nCT induced significant fluid accumulation in li-
gated loops, while 1,000-fold higher levels (100 
 
m
 
g) of mCTs
were nontoxic (Table 1).
 
Adjuvant Properties of mCTs.
 
To assess the immunologic
properties of mCTs, groups of mice were immunized with
OVA combined with each mCT or with nCT as a control.
Immunization with OVA alone did not result in significant
anti-OVA Ab responses, and admixture of OVA with rCT-B
also failed to support anti-OVA Ab responses; however,
both mCTs and nCT enhanced serum anti-OVA Abs and
these responses were mainly of the IgG isotype (Fig. 1 
 
A
 
).
Further, anti-OVA Abs were largely restricted to IgG1 with
less IgG2b subclass response (Fig. 1 
 
B
 
). Significant numbers
of splenic OVA-specific IgG AFCs were noted in mice given
OVA combined with mCTs or with nCT, whereas low
numbers of AFCs were observed in mice given OVA alone
or OVA with rCT-B (Fig. 1 
 
C
 
). Thus, both mCTs in-
duced an Ab pattern remarkably similar to the serum Ab
responses which resulted from use of nCT as adjuvant.
Mice immunized with OVA and mCTs or nCT as adju-
vant also showed significant CT-B–specific IgG responses.
Although IgG anti–CT-B responses were also seen in mice
given rCT-B, the titers were 
 
z
 
100-fold lower than seen
when either mCTs or nCT were given (Fig. 1 
 
A
 
). In addi-
tion, mCTs and nCT induced high levels of CT-B–specific
IgG1 and IgG2b Abs (Fig. 1 
 
B
 
). Large numbers of CT-B–spe-
cific IgG AFCs were present in splenic cells from mice im-
munized with mCTs or with nCT, whereas much lower
numbers of AFCs were seen in mice immunized with rCT-B
(Fig. 1 
 
C
 
).
 
IgE Responses by mCTs. Past studies have shown that
Table 1. Comparison of Biologic, Enzymatic, and Toxic
Activity of mCTs and nCT
Adjuvant
assessed
CHO
assay*
cAMP
induction‡
ADP-
ribosyltransferase
activity§
Ileal loop
testi
pg/ml pmol/mg cpm ng
nCT 1 739 6 127 4,669 6 256 100
S61F .106 8.3 6 1.8 93 6 12 .105
E112K .106 6.2 6 2.2 98 6 15 .105
PBS — 9.7 6 2.2 98 6 6—
* CHO cells were cultured in tissue culture chamber with log10 dilu-
tions of each toxin for 24 h and the toxic effects were defined as spindle
formation in .20% of cultured cells.
‡CHO cells were cultured with 1 ng/ml of each toxin for 24 h and
cAMP assessed by an enzyme immunoassay system. The protein in 5%
trichloroacetic acid pricipitates was determined and concentrations of
cAMP were expressed as the mean pmol of cAMP per mg of protein 6
SEM of three samples. The results are representative of three experi-
ments.
§The radioactivity of ADP-ribosylated agmatine induced by mCTs or
nCT in a 50-ml aliquot of the assay mixture was expressed as the mean
cpm 6 SEM of six samples. The results are representative of three sepa-
rate experiments.
iThe enterotoxicity of mCTs and nCT was examined using an ileal
loop test, where mice were anesthetized, and 100 ml of PBS containing
different levels of each toxin were injected into a 2-cm ileal loop. Loops
were examined 18 h later and the ratio of fluid to length was defined as
positive when the ratio was .40 ml/cm.1206 Nontoxic Mutants of Cholera Toxin Induce Th2-type Responses
CT induces marked increases in both total and Ag-specific
IgE Abs after mucosal immunization (11). We have used
two sensitive assays to detect increased total serum IgE as
well as Ag-specific IgE Abs in mice given OVA combined
with mCTs or with nCT as adjuvant. In these studies,
maximum IgE responses peaked by 3 wk, and although dif-
ferences in total IgE levels were not significant in mice
given mCTs or nCT (Table 2), anti-OVA IgE titers were
lower in mice given mCT S61F (P ,0.05), whereas CT-
B–specific IgE Abs were depressed in mice given mCTs
S61F or E112K when compared with nCT (P ,0.01) (Ta-
ble 2). In mice given OVA alone or OVA plus rCT-B,
neither total nor Ag-specific IgE responses were noted.
Mutant CTs, like nCT, Induce CD41 Th2 Responses.
Mucosal administration of CT with protein Ags induces
Ag-specific CD41 T cell responses with an overall Th2
phenotype (10, 11). Of interest was our finding that both
mCTs also induced OVA-specific CD41 T cell prolifera-
tive responses, which were comparable to those seen in
mice given nCT as adjuvant (Fig. 2). Moreover, splenic
OVA-specific CD41 T cells from mice given OVA to-
gether with mCTs produced high levels of Th2-type cy-
tokines (IL-4, IL-5, IL-6, and IL-10), which were compa-
rable to those seen when nCT was used as adjuvant (Fig. 3).
On the other hand, CD41 T cells from mice given OVA
alone or OVA plus rCT-B did not produce detectable lev-
els of cytokines other than IFN-g when stimulated with
OVA. Abundant Th2-type cytokine-specific mRNA was
present in OVA-specific CD41 T cell cultures taken from
mice given OVA combined with mCTs or with nCT, but
was not detected in CD41 T cells from mice given OVA
alone or OVA plus rCT-B (Fig. 3). Further, IFN-g was
detected at low levels in all cultures including OVA-stimu-
lated controls from unimmunized mice. Splenic CT-B–spe-
cific CD41 T cells from mice given mCTs or nCT also
demonstrated significant proliferation (Fig. 2) and high lev-
els of Th2-type with low but detectable levels of Th1-type
cytokines (data not shown). The quantitative RT-PCR re-
sults together with levels of secreted cytokines were consis-
tent with our previous studies (10) which showed that nCT
induces CD41 Th2-type responses.
Discussion
The present study shows that enzyme and toxic functions
induced by CT could be eliminated through derivation of
mutants with single amino acid substitutions, presumably
Figure 1. OVA- and CT-B–specific Ab responses after subcutaneous
immunization with OVA combined with mCTs or nCT as adjuvants. Se-
rum IgM, IgG, and IgA responses (A) and IgG subclass responses (B) were
assessed by endpoint ELISA. Splenic Ag-specific AFCs (C) were deter-
mined by ELISPOT assay. Groups of C57BL/6 mice were immunized
subcutaneously with 100 mg of OVA alone or together with 10 mg of
rCT-B, 1 mg of nCT, or 10 mg of mCTs, S61F, or E112K, on days 0 and
14. All assays were performed on samples from mice taken 1 wk after the
last immunization. Bars represent the mean Ab titer and mean number of
AFCs 6 SEM in each group of 10 mice and the data are representative of
three separate experiments.
Table 2. IgE Responses Induced by mCTs and nCT
Treatment group* Total IgE‡
Ag specific-IgE
(reciprocal log2 titer)‡
OVA CT-B
ng/ml
OVA alone 128 6 32 3.5 6 0.9 ,3
OVA 1 rCT-B 134 6 46 3.6 6 1.1 ,3
OVA 1 nCT 1,408 6 402 9.4 6 0.7 5.5 6 0.8
OVA 1 S61F 1,267 6 416 7.3 6 0.9§ 3.1 6 0.3i
OVA 1 E112K 1,086 6 313 7.8 6 0.7 ,3i
*Mice were immunized subcutaneously with 100 mg of OVA alone or
together with 10 mg of rCT-B, 1 mg of nCT, or 10 mg of mCTs,
S61F, or E112K, on days 0 and 14. Each group contained 10 mice.
The results are representative of three separate experiments.
‡IgE responses on day 21 were determined by ELISA ( total) and lumi-
nometric assay (Ag-specific).
§Significantly lower (P ,0.05 when compared with nCT).
iSignificantly lower (P ,0.01 when compared with nCT).1207 Yamamoto et al.
in or closely associated with the ADP-ribosyltransferase
cleft of the A subunit (16). In particular, two mutants S61F
and E112K, were shown to (a) be devoid of ADP-ribosyl-
transferase activity, (b) be unable to induce increases in in-
tracellular cAMP, and (c) fail to elicit fluid accumulation in
mouse-ligated ileal loops. Even more importantly, the
mCTs retained their ability to boost Ab responses to the
coadministered protein OVA as well as enhance Ab re-
sponses to the molecule itself, e.g., to CT-B. These adju-
vant effects of mCTs were due to the A subunit portion of
the molecule, since coadministration of rCT-B at much
higher concentrations with OVA did not enhance anti-
OVA Ab responses. Furthermore, both mCTs induced sig-
nificant OVA-specific CD41 T cell proliferative responses,
with subsequent production of IL-4, IL-5, IL-6, and IL-10
(Th2-type) that were comparable to a Th2-type response
seen when nCT was used as adjuvant. These findings have
important implications, since we have shown that CT elic-
its adjuvanticity by induction of Ag-specific CD41 Th cells
secreting Th2-type cytokines, which in turn provide B cell
help for serum IgG1, IgG2b, IgA, and IgE and mucosal S-IgA
Ab responses (10, 11). Thus, we conclude from these re-
sults that both mCTs and nCT act as adjuvants by the same
mechanism to enhance the immunogenicity of a coadmin-
istered, unrelated protein, and that this pathway is indepen-
dent of ADP-ribosyltransferase activity.
Several groups have studied potential mechanisms for the
adjuvant effects induced by CT and LT, and studies have
also focused on separating the ADP-ribosyltransferase func-
tion from adjuvanticity, e.g., removal of toxic effects while
retaining the beneficial effects of the molecule. Since the A
subunit is responsible for toxicity, several studies have sug-
gested that CT-B can be used as adjuvant. Although CT-B
alone appeared to have adjuvant properties in some studies
(29, 30), CT-B prepared from holotoxin generally contains
a small amount of CT-A, which is sufficient to enhance the
immune responses (31). Others have assessed the adjuvan-
ticity of an LT mutant without ADP-ribosyltransferase ac-
tivity (E112K) and rCT-B (13), and their results showed
that neither mutant nor rCT-B could enhance the immune
response to a coadministered protein. This led to the con-
clusion that ADP-ribosyltransferase activity was essential
for adjuvanticity of both LT and CT (13).
In vitro studies in a variety of cells, e.g., B cells (32), T
cell lines (33, 34), macrophages (35), and epithelial cells (36),
were used to assess the potential mechanism whereby CT
and LT enhance the immune response. In most of these
studies, it was concluded that adjuvanticity of CT resulted
from the ADP-ribosyltransferase activity, i.e., induction of
increased intracellular cAMP formation. In one study, CT
as well as forskolin was shown to inhibit T cell receptor–
mediated IL-2 production and proliferation in cloned Th1
cells, but not IL-4 production and proliferation in a clone
of Th2 cells, indicating that Th1 and Th2 cells differ in
their sensitivity to increases in intracellular cAMP (34).
However, based on our results, mCTs retained adjuvantic-
ity despite a lack of ADP-ribosyltransferase activity. Fur-
thermore, the IgG subclass Ab responses induced by mCTs
were largely IgG1 and IgG2b, and OVA-specific CD41 T
cells from mice given mCT were of the Th2 type, a pattern
essentially identical to those results obtained with nCT. Thus,
in marked contrast to previous observations, our findings
indicate that adjuvanticity of CT can be dissociated from
ADP-ribosyltransferase activity and enterotoxicity, and the
CD41 Th2-type T cell responses induced by CT are due
to a pathway separate from the adenyl cyclase system.
An interesting aspect of this study was that the mCT
E112K exhibited significant adjuvant activity, whereas an
LT mutant E112K was not effective (13). Although CT
and LT share a significant degree of homology (z80%
amino acid sequence homology; 1) and some antibodies in-
duced to CT-B cross-react with LT-B and vice versa, sig-
nificant differences exist. Although CT and LT are both
potent adjuvants, the molecules differ in terms of the na-
ture of CD41 Th subsets induced and the profile, isotype,
and subclass of Abs induced. For example, CT elicits adju-
Figure 2. OVA- and CT-
B–specific CD41 T cell prolifera-
tive responses. Groups of C57BL/6
mice were immunized subcuta-
neously with 100 mg of OVA
alone or together with 10 mg of
rCT-B, 1 mg of nCT, or 10 mg
of mCTs, S61F, or E112K, on
days 0 and 14. Purified splenic
CD41 T cells were cultured at a
density of 2 3 106 cells/ml in the
presence of 1 mg/ml of OVA or
107 CT-B–coated beads/ml, T
cell–depleted, irradiated splenic
feeder cells (2.5 3 106 cells/ml)
and IL-2 (10 U/ml) in complete
medium. Bars represent the mean
stimulation index 6 SEM in each
group. Each group contained 10
mice and are representative of
three separate experiments.1208 Nontoxic Mutants of Cholera Toxin Induce Th2-type Responses
Figure 3. Cytokine production from OVA-specific splenic CD41 T cells. Molecules of cytokine-specific mRNA were determined by quantitative
RT-PCR using rRNA internal standards. Cytokine production was determined by ELISA. The scale of each figure corresponds to mRNA molecules and
protein levels produced by nonimmunized CD41 T cells stimulated with anti-CD3 mAb. Bars represent the mean cytokine profile 6 SEM in each group.
ND indicates that the molecules were not detected. Each group contained five mice and are representative of three separate experiments.1209 Yamamoto et al.
vanticity by promoting Ag-specific CD41 Th2-type re-
sponses associated with high levels of IL-4 and IL-5 pro-
duction with provision of help for IgG1 subclass, IgE and
S-IgA responses (10, 11), whereas LT promotes both Th1-
and Th2-type responses with high levels of IFN-g and IL-5
production and subsequent IgG1, IgG2a, IgG2b subclass and
S-IgA Ab responses (12). Furthermore, oral administration
of CT as adjuvant failed to enhance Ag-specific S-IgA re-
sponses in IL-4 gene disrupted (IL-42/2) mice (37), whereas
LT was able to induce Ag-specific mucosal S-IgA as well as
serum IgG responses in both IL-42/2 and IL-41/1 mice
(our unpublished data). These differences cannot be as-
cribed to ADP-ribosyltransferase activity which both mole-
cules share.
The finding that 10-fold higher doses of mCTs were re-
quired to elicit comparable adjuvant responses as nCT also
merits discussion. Two broad possibilities could explain these
differences. First, the site-directed mutagenesis step may have
caused a conformational change in the actual site responsi-
ble for adjuvanticity of the CT molecule. If this is correct,
then the responsible site for adjuvanticity may be located
close to the ADP-ribosyltransferase active center (16). The
second possibility is that adjuvanticity of CT may be de-
rived from two (or more) mechanisms, which include ADP-
ribosyltransferase activity, since several reports have shown
that intracellular cAMP accumulation after ADP-ribosyla-
tion activates T cell (33) and epithelial cell lines (36). Of
importance to this point is that in most in vitro studies, CT
has been shown to inhibit mitogen-, Ag-, or anti-CD3–
induced T cell proliferative responses (38), whereas in vivo
studies have shown that CT induces strong Ag-specific
CD41 T cell responses which provide effective help for Ab
responses (10, 11). Thus, in vitro studies may result in di-
rect inhibition of signal transduction pathways for T cells,
whereas CT in vivo may transduce activation pathways that
include the induction of CD41 Th2-type responses.
In summary, this study has shown that the newly devel-
oped mCTs, S61F, and E112K, retain adjuvanticity despite
a complete lack of ADP-ribosyltransferase activity and sub-
sequent enterotoxicity. Further, mCTs induced CD41
Th2-type responses, while Ag-specific IgE Abs in the se-
rum of mice immunized with OVA plus mCTs were lower
than those induced by nCT. These findings indicate that
these mCTs may have significant advantages when used as
adjuvants. Our results not only show that adjuvanticity of
CT can be separated from ADP-ribosytransferase activity
and enterotoxicity, but that these mCTs could be ideal
candidates for a nontoxic mucosal adjuvant. We are cur-
rently assessing the mucosal adjuvanticity of these mCTs.
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